Knowledge of the energy deposition in different eye components is a critical decision-making to the overall effectivity of ocular melanoma treatment with plaques loaded with low-energy sources. The aim of this study is using the GATE 8.2 Monte Carlo code to calculate the 3D dose distribution in a realistic eye model. At first, we validated the GATE simulation for I, Pd, and Cs seeds by calculating the dose rate constant, radial dose function, and anisotropy function of the three radioactive sources. Then, a 12-mm Collaborative Ocular Melanoma Study (COMS) eye plaque was simulated in the eye phantoms to evaluate dose distribution due to low-energy gamma emitters on the three simulated medium-sized tumors. The findings of this study indicate that the estimated doses received by different eye substructures strongly depend on the source type. The results show that the type of seeds used in the plaque, as well as the size of the eye tumor, have significant effects on the dose deposition in the different structures of the eye and dose deposition uniformity. Moreover, comparing different radionuclides showed that the COMS plaque fully loaded with Pd presents a higher dose delivery to the tumor and a lower one to the critical structures for medium-sized tumors, while the plaque fully loaded with Cs produces the most uniform dose distribution in the tumor.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apradiso.2022.110146DOI Listing

Publication Analysis

Top Keywords

dose distribution
16
eye
8
eye model
8
ocular melanoma
8
dose
8
medium-sized tumors
8
dose deposition
8
plaque fully
8
fully loaded
8
comparison dose
4

Similar Publications

The treatment regimen for [Lu]Lu-prostate-specific membrane antigen (PSMA) 617 therapy follows that of chemotherapy: 6 administrations of a fixed activity, each separated by 6 wk. Mathematic modeling can be used to test the hypothesis that the current treatment regimen for a radiopharmaceutical modality is suboptimal. A mathematic model was developed to describe tumor growth during [Lu]Lu-PSMA therapy.

View Article and Find Full Text PDF

The tumor microenvironment characterized by heterogeneously organized vasculatures causes intra-tumoral heterogeneity of oxygen partial pressure at the cellular level, which cannot be measured by current imaging techniques. The intra-tumoral cellular heterogeneity may lead to a reduction of therapeutic effects of radiation. The purpose of this study was to investigate the effects of the heterogeneity on biological effectiveness of H-, He-, C-, O-, and Ne-ion beams for different oxygenation levels, prescribed dose levels, and cell types.

View Article and Find Full Text PDF

A preliminary study was conducted using electronic portal imaging device (EPID) based dose verification in pre-treatment and in vivo dose reconstruction modes for breast cancer intensity-modulated radiation therapy (IMRT) technique with known repositioning set-up errors. For 43 IMRT plans, the set-up errors were determined from 43 sets of EPID images and 258 sets of cone beam computed tomography images. In-house developed Edose software was used to reconstruct the dose distribution using the pre-treatment and on-treatment (in vivo) EPID acquired fluence maps.

View Article and Find Full Text PDF

Objectives: The purpose of this study was to investigate the fundamental properties of spot-scanning proton beams and compare them to Monte Carlo (MC) simulations, both with and without CT calibration, using spatially diverse combinations of materials.

Methods: A heterogeneous phantom was created by spatially distributing titanium, wax, and thermocol to generate six scenarios of heterogeneous combinations. Proton pencil beams ranging in energy from 100 to 226.

View Article and Find Full Text PDF

This study aimed to identify radiotherapy dosimetric parameters related to local failure (LF)-free survival (LFFS) in patients with lung and liver oligometastases from colorectal cancer treated with stereotactic body radiotherapy (SBRT). We analyzed 75 oligometastatic lesions in 55 patients treated with SBRT between January 2014 and December 2021. There was no constraint or intentional increase in maximum dose.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!